Search

BACKGROUND: Prepubertal patients receiving chemotherapy are relatively resistant to cyclophosphamide-induced germinal cell alterations. We studied the possible protective effect of testosterone and triptorelin to inhibit gonadal activity in men and women receiving cyclophosphamide, respectively. STUDY DESIGN: Nonrandomized trial. SETTING & PARTICIPANTS: 28 consecutive patients, 11 men and 17 women, from a university medical center with various forms of glomerulonephritis, treated with cyclophosphamide. INTERVENTION: Men received cyclophosphamide plus testosterone; women were divided into 2 groups: 13 patients (group A) received cyclophosphamide plus triptorelin; 4 (group B) received only cyclophosphamide. OUTCOMES & MEASUREMENTS: Serum follicle-stimulating hormone (FSH) and serum luteinizing hormone levels and, in addition, sperm counts and testosterone levels in men and estradiol levels in women were measured before and after treatment with cyclophosphamide. RESULTS: All 10 men became azoospermic or severely oligospermic during treatment; after 12 months, all except 1 had a normal sperm count and FSH levels were normal. In women during cyclophosphamide therapy, amenorrhea occurred in all patients. After cessation of therapy, all women in group A started to menstruate regularly, and at the end of follow-up, ovulatory cycles were demonstrated in all women. Hormone levels showed no significant changes throughout the observation period. Six women conceived, and the pregnancies were brought to term successfully without complications. In group B, all 4 women developed sustained amenorrhea; serum FSH and luteinizing hormone levels at the end of therapy and follow-up were significantly higher with respect to baseline; estradiol levels at the end of follow-up were significantly lower compared with baseline and corresponding values in group A. LIMITATIONS: The substudy in men is uncontrolled, the substudy in women is nonrandomized. CONCLUSIONS: The study suggests a protective effect of testosterone and triptorelin against cyclophosphamide-induced gonadal damage in men and women with various forms of kidney disease, respectively. [ABSTRACT FROM AUTHOR]

1 Luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin levels were measured in twenty paediatric patients receiving sodium valproate (30 mg/kg body weight daily) and in ten control subjects under control conditions and following LRH-TRH administration. In addition, baseline GH levels were measured in the two groups. 2 No significant differences were observed between the basal and stimulated hormone levels in the two groups. Although sodium valproate may act as anticonvulsant by increasing GABA levels in the central nervous system, the present data indicate that a central GABAergic pathway is probably not involved in the control of gonadotrophin and prolactin secretion. [ABSTRACT FROM AUTHOR]

Relationships between heart rate recovery after exercise (HRR, baseline heart rate variability measures (HRV), and time to perform a 10Km running trial (t10Km) were evaluated in "master" athletes of endurance to assess whether the measured indexes may be useful for monitoring the training status of the athletes. Ten "master" athletes of endurance, aged 40-60 years, were recruited. After baseline measures of HRV, the athletes performed a graded maximal test on treadmill and HRR was measured at 1 and 2 minutes from recovery. Subsequently they performed a 10Km running trial and t10Km was related to HRV and HRR indexes. The time to perform a 10Km running trial was significantly correlated with baseline HRV indexes. No correlation was found between t10Km and HRR. Baseline HRV measures, but not HRR, were significantly correlated with the time of performance on 10km running in "master" athletes. The enhanced parasympathetic function at rest appears to be a condition to a better performance on 10km running. HRV can be simple and useful measurements for monitoring the training stratus of athletes and their physical condition in proximity of a competition., Competing Interests: Conflict of Interest The authors declare no conflicts of interests derived from the outcomes of this stud.